Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma:
prognostic significance of E2F-1 and p16INK4A.

Leukemia  (ENGLAND)  May 2000  14 (5) p898-904  ISSN: 0887-6924

    In the present study, we analysed 34 de novo diffuse large B cell
lymphoma (DLCL)from a population-based lymphoma registry for alterations
of the RB1 pathway at the genetic (RB1 and CDK4) and protein (pRb,
cyclin D1, cyclin D3, CDK4, and E2F-1) level.  

The results were correlated with the data from our previous studies of
CDKN2A deletion and hypermethylation, other p53 pathway components,
p27Kip1 expression, and proliferation, as well as with clinical outcome,
including prognosis.  We found aberrant pRb expression in four (12%) of
34 DLCLs.  One of these had a point mutation in intron 3 10 bp
downstream of exon 3 generating a novel splice signal.  Seven tumours
(21%) showed cyclin D3 overexpression, including all three thyroid
lymphomas (P = 0.006).  Cyclin D3 overexpression and p16INK4A/pRb
aberrations were mutually exclusive, supporting an oncogenic role for
cyclin D3 in DLCL. p16INK4A inactivation, cyclin D3 overexpression, or
aberrant pRb expression was identified in 18 of 34 DLCLs (53%). 
Combining these results with our previous p53 pathway studies showed
that 82% of the de novo DLCLs had alterations of these pathways, and
that both pathways were altered in 13 cases (38%).  Low E2F-1 expression
was associated with treatment failure (P = 0.020), and multivariate
analysis of overall survival identified both 

low E2F-1 expression (relative risk = 6.9; P = 0.0037) and p16INK4A
inactivation (relative risk = 3.3; P = 0.0247) as independent prognostic
markers.  These data support a role of E2F-1 as tumour suppressor gene
in lymphoma and strongly suggest that the RB1 and p53 pathways are
important in the development of de novo DLCL.  Furthermore, low E2F-1
expression and p16INK4A inactivation may serve as prognostic markers for
patients with this type of lymphoma.

Prognostic clinicopathologic factors, including immunologic expression
in diffuse large B-cell lymphomas.

  Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki
C; Kikuchi M

Pathology international  (AUSTRALIA)  Dec 1999  49 (12) p1043-52  ISSN: 

  The aim of this study was to assess the clinical significance and
potential prognostic value of the expression of a panel of surface
markers, proliferating, suppressor and oncogenic proteins in diffuse
large B-cell lymphomas (DLBCL).

Biopsies were collected from 158 patients with DLBCL and analyzed 

immunohistochemically for p53, p21/WAF1, bcl-2, cyclin-D1, bcl-6, mdr,
CD5, CD30, epithelial membrane antigen (EMA), Ki-67 and c-myc positive
tumor cells.  Among these, 76 young and middle-aged patients (20-65
years) were selected to investigate the relationship between protein
expression, clinical features, and survival.  Survival analysis showed
that advanced stage, high lactic dehydrogenase level, and high
International Prognostic Index (IPI) were poor prognostic factors
associated with a shorter overall survival (OS) and disease-free
survival (DFS) times.  A high p53 expression and low bcl-6 expression
were associated with a shorter DFS time.  The histological variant type,
cyclin-D1+ CD5+ DLBCL, positive epithelial membrane antigen (EMA+) CD30-
DLBCL, high bcl-2 expression, and low Ki-67 proliferation activity
tended to be associated with worse survival, but the correlations were
not statistically significant.  In the multivariate analysis, the most
significant factors were age, followed by IPI and last p53.  The
expression of p21/WAF1, mdr, and c-myc proteins did not influence OS and
DFS.  The expression of p53 and bcl-6 proteins may be useful prognostic
indicators in DLBCL.  Cyclin-D1+ CD5+ or EMA+ CD30- DLBCL tended to
predict a worse survival and may probably bear a significant prognostic
value worthy of consideration.  Overall, clinical factors appeared to be
more important than biologic parameters in determining the prognosis of
diffuse large B-cell lymphomas.

Expression of p16INK4A and p14ARF in hematological malignancies.

  Taniguchi T; Chikatsu N; Takahashi S; Fujita A; Uchimaru K; Asano S;
Fujita T; 

Leukemia  (ENGLAND)  Nov 1999  13 (11) p1760-9  ISSN: 0887-6924

The INK4A/ARF locus yields two tumor suppressors, p16INK4A and p14ARF,
and is frequently deleted in human tumors.  We studied their mRNA
expressions in 41 hematopoietic cell lines and in 137 patients with
hematological malignancies; we used a quantitative reverse
transcription-PCR assay.  Normal peripheral bloods, bone marrow and
lymph nodes expressed little or undetectable p16INK4A and p14ARF mRNAs,
which were readily detected in 12 and 17 of 41 cell lines, respectively.
 Patients with hematological malignancies frequently lacked p16INK4A
expression (60/137) and lost p14ARF expression less frequently (19/137,
13.9%).  Almost all patients without p14ARF expression lacked p16INK4A
expression, which may correspond to deletions of the INK4A/ARF locus. 
Undetectable p16INK4A expression with p14ARF expression in 41 patients
may correspond to p16INK4A promoter methylation or to normal expression
status of the p16INK4A gene.  All patients with follicular lymphoma
(FL), myeloma or acute myeloid leukemia (AML) expressed p14ARF while
nine of 23 patients with diffuse large B cell lymphoma (DLBCL) lost
p14ARF expression.  Patients with ALL, AML or blast crisis of chronic
myelogenous leukemia expressed abundant p16INK4A mRNAs more frequently
than patients with other diseases (12/33 vs 6/104, P < 0.01).  Patients
with FL and high p14ARF expression had a significantly shorter survival
time while 

survival for patients with DLBCL and increased p14ARF expression tended
to be longer.  These observations indicate that p16INK4A and p14ARF
expression is differentially affected among hemato- logical malignancies
and that not only inactivation but also increased expression may have
clinical significance.

Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in
marginal zone B-cell lymphoma: An interphase fluorescence in situ
hybridization study.

  Dierlamm J; Stefanova M; Wlodarska I; Hinz K; Maes B; Michaux L; Stul
M; Verhoef G; Thomas J; De Wolf-Peeters C; Van den Berghe H; Hossfeld
DK; Hagemeijer A

Cancer genetics and cytogenetics  (UNITED STATES)  Jul 1 2000  120 (1)
p1-5  ISSN: 

The genetic mechanisms underlying the genesis, disease progression, and
high-grade transformation of marginal zone B-cell lymphoma (MZBCL) are
poorly understood.  We analyzed 33 cases of histologically and
immunophenotypically well-characterized MZBCL (12 extranodal, 11 nodal,
and 10 splenic MZBCL; 27 at primary diagnosis and six during the course
of disease) by dual-color interphase fluorescence in situ hybridization
(FISH) for deletions of tumor suppressor genes.  We investigated loci
known to play a role in the genesis or disease progression of other
subtypes of lymphoid malignancies, namely the P53 gene (17p13), the
retinoblastoma gene (RB,13q14), the D13S25 locus (13q14), and the
P16(INK4A) gene (9p21).  Heterozygous deletions of P53 were detected in
three out of the 33 cases, including two splenic and one extranodal
MZBCL.  One of these patients was analyzed at primary diagnosis and two
during the course of disease.  Heterozygous deletions of the RB gene
(nodal MZBCL) and D13S25 (splenic MZBCL) were found in one case each. 
P16 deletions were not detected in any of our cases.  We conclude that
deletions of the analyzed tumor suppressor genes are relatively rare in
MZBCL, which contrasts with the findings in some other subtypes of NHL.

Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in
Hodgkin's lymphomas.

  Kanavaros P; Stefanaki K; Vlachonikolis J; Eliopoulos G; Kakolyris S;
Rontogianni D; Gorgoulis V; Georgoulias V

Histology and histopathology  (SPAIN)  Apr 2000  15 (2) p445-53  ISSN: 

The aim was to investigate the combined immunoexpression of p53, p21,
bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas (HL) and
correlate expression patterns with the histotype and the Epstein-Barr
Virus (EBV) status.  Paraffin-sections from 56 cases of HL (18 nodular
sclerosis and 38 mixed cellularity) and from ten "reactive" lymph nodes
were investigated.  P53, p21, bcl-2, bax, Rb and Ki67 proteins were
detected in Hodgkin and Reed-Sternberg (HRS) cells in 35/56, 56/56,
24/56, 23/56, 56/56 and 56/56 cases of HL, respectively.  No correlation
was found between the expression of each protein and the EBV status or
the histotype of HL.  Comparison between p53 and p21 staining revealed
two patterns: a) p53+/p21+ (35 cases); and b) 

p53-/p21+ (21 cases).  The pattern p53+/p21+ suggests wild type p53
protein able to induce the expression of p21 while the p53-/p21+ pattern
suggests p53-independent p21 expression.  These results are consistent
with the interpretation that inactivating p53 gene mutations may be rare
in HL.  Comparison between bcl-2 and bax staining showed a statistically
significant relationship (p<0.001) for coexpression (19 cases)or absence
of expression of both proteins (28 cases) in HRS cells.  In contrast,
bax expression was observed in most lymphoid cells in all "reactive"
lymph nodes.  Since the proapoptotic bax protein may act as tumour
suppressor it is possible that the absence of this protein in HRS cells
in a substantial proportion of HL may confer growth advantage and play a
role in their pathogenesis.  This could suggest bax gene alterations in
some HL since in other studies acute lymphoblastic leukaemia cell lines
demonstrate bax gene mutations with loss of bax immunoexpression. 
Another possibility is that reduced bax expression may be due to post
transcriptional regulation, as was described in lymphoma cell lines. 
Comparison between Rb and Ki67 

staining disclosed two main deviations from the normal parallel
relationship in reactive lymph nodes: a) 2 cases with low Rb and high
Ki67 expression possibly reflecting loss of Rb expression due to
chromosome loss or to other abnormalities in the structure or the
expression of Rb gene; and b) 9 cases with high RB and low Ki67 possible
reflecting an attempt of Rb protein in excess to induce cell cycle
arrest.  Taken together, our findings provide combined
immunohistological evidence for deregulated expression of cell-cycle and
apoptosis-related proteins, that may play a role in the pathogenesis of

Apoptotic death of tumor cells correlates with chemosensitivity,
independent of p53 or bcl-2.

  Wu GS; El-Deiry WS  

  Clinical cancer research  (UNITED STATES)  Apr 1996  2 (4) p623-33  

p53 has been implicated as a determinant of chemosensitivity and
radiosensitivity. We measured chemosensitivity of human tumor cell lines
(n = 11), with or without wild-type p53, following exposure to
clinically useful chemotherapeutic drugs (n = 4).  Chemosensitivity and
apoptosis induction were correlated independently of p53 status or Bcl-2
protein levels in vitro.  Wild-type p53 correlated with chemosensitivity
in ovarian carcinoma and some Burkitt's lymphoma cells, but not in
leukemia or lung cancer.  Bcl-2 levels correlated with chemoresistance
only in Burkitt's lymphoma. p53-dependent p21(WAF1/CIP1) induction and
cell cycle arrest occurred at sublethal doses of chemotherapy, whereas
at lethal doses of chemotherapy apoptotic death was observed, consistent
with models proposing a relationship between the level of DNA damage
versus survival or death.  Loss of apoptosis induction was observed in
drug-resistant ML-1 and HL-60 leukemia cells, without changes in p53 or
Bcl-2.  Targeted loss of p53 protein in H460 lung cancer cells using
HPV-16 E6 inhibited the etoposide-induced G1 checkpoint but did not
decrease chemosensitivity.  Our studies suggest that the simple
measurement of apoptosis induction may be a useful predictor of
chemosensitivity, at least in vitro, and confirm that p53 status and
Bcl-2 expression may be useful predictors of chemosensitivity in certain
cell types.